Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple therapy for smoking cessation
NCT02681510Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of varenicline + nicotine patch and nicotine patch in Tobacco Use Disorder (TUD), sponsored by University of Wisconsin–Madison. Primary endpoint: Number of Participants With Adverse Events at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
varenicline + nicotine patchnicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT02681510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681510.